Levofloxacin in first-line eradication regimens for Helicobacter pylori: Better test antibiotic susceptibility before treating

Gut

Volumn 60, Issue 11, 2011, Pages 1605-

  Molina Infante, Javier ^a   Gisbert, Javier P ^b  

^a HOSPITAL SAN PEDRO   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CLARITHROMYCIN; LEVOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; DRUG DOSE REGIMEN; GEOGRAPHIC DISTRIBUTION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; INFECTION CONTROL; LETTER; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; TREATMENT DURATION;

ANTI-BACTERIAL AGENTS; CLARITHROMYCIN; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; OFLOXACIN;

EID: 80053560846     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2010.233015     Document Type: Letter

References (5)

1. Romano M, Cuomo A, Gravina AG, et al. Empirical levofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori: a randomised trial. Gut 2010;59:1465-70.
2. Molina-Infante J, Perez-Gallardo B, Fernandez- Bermejo M, et al. Clinical trial: clarithromycin vs levofloxacin in first-line triple and sequential regimens for H. pylori eradication. Aliment Pharmacol Ther 2010;31:1077-84.
3. Cibrelus LA, Perez de Ayala A, Alarcon T, et al. In vitro efficiency of ciprofloxacin and rifampicin as potential second-line treatment in Spanish Helicobacter pylori clinical isolates. Helicobacter 2006;11:402.
4. Gisbert JP, Calvet X, O'Connor A, et al. Sequential therapy for Helicobacter pylori infection: a critical review. J Clin Gastroenterol 2010;44:313-25.
5. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing of antibiotic resistance. Gut 2010;59:1143-53.